<DOC>
	<DOCNO>NCT02456688</DOCNO>
	<brief_summary>This clinical research study ass pharmacokinetics safety Imrecoxib patient impair hepatic function compare healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetics Imrecoxib Subjects With Hepatic Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>All subject : Between age 18 70 year , BMI 18~ 29kg/m2 . In good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test value ( except value relate hepatic insufficiency ) . Hepatic impaired subject : Hepatocirrhosis subject verify Bmode ultrasonography , CT , MRI Biopsy . A ChildPugh Classification score clinically determine Class B . All subject : History hypersensitivity Imrecoxib component . Subjects diagnose tumor . History current clinically important systemic illness , include limited cardiovascular , pulmonary , renal , hematological , gastrointestinal , endocrinological , immunological , dermatological , psychiatric disease . Have use drug substance ( include herbal supplement ) know inhibit induce cytochrome P450 enzymes include cytochrome P450 3A4 , cytochrome P450 2C8 cytochrome P450 2C9 within 28 day prior first dose throughout study . Have take investigational drug participate clinical trial within 90 day prior first dose study drug study . Hepatic impaired subject : Subjects hepatic failure , severe complication cause Hepatocirrhosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>